JPWO2021113754A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021113754A5
JPWO2021113754A5 JP2022533416A JP2022533416A JPWO2021113754A5 JP WO2021113754 A5 JPWO2021113754 A5 JP WO2021113754A5 JP 2022533416 A JP2022533416 A JP 2022533416A JP 2022533416 A JP2022533416 A JP 2022533416A JP WO2021113754 A5 JPWO2021113754 A5 JP WO2021113754A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
individual
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022533416A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505219A (ja
JP7704751B2 (ja
JP2023505219A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/063468 external-priority patent/WO2021113754A1/en
Publication of JP2023505219A publication Critical patent/JP2023505219A/ja
Publication of JP2023505219A5 publication Critical patent/JP2023505219A5/ja
Publication of JPWO2021113754A5 publication Critical patent/JPWO2021113754A5/ja
Priority to JP2025106921A priority Critical patent/JP2025138745A/ja
Application granted granted Critical
Publication of JP7704751B2 publication Critical patent/JP7704751B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022533416A 2019-12-06 2020-12-04 再発性および/または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用 Active JP7704751B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025106921A JP2025138745A (ja) 2019-12-06 2025-06-25 再発性および/または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962944809P 2019-12-06 2019-12-06
US62/944,809 2019-12-06
EP20315186.5 2020-04-17
EP20315186 2020-04-17
US202063023198P 2020-05-11 2020-05-11
US63/023,198 2020-05-11
US202063037353P 2020-06-10 2020-06-10
US63/037,353 2020-06-10
US202063094833P 2020-10-21 2020-10-21
US63/094,833 2020-10-21
PCT/US2020/063468 WO2021113754A1 (en) 2019-12-06 2020-12-04 Use of isatuximab for the treatment of relapsed and/or refractory multiple myeloma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025106921A Division JP2025138745A (ja) 2019-12-06 2025-06-25 再発性および/または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用

Publications (4)

Publication Number Publication Date
JP2023505219A JP2023505219A (ja) 2023-02-08
JP2023505219A5 JP2023505219A5 (https=) 2023-12-08
JPWO2021113754A5 true JPWO2021113754A5 (https=) 2023-12-08
JP7704751B2 JP7704751B2 (ja) 2025-07-08

Family

ID=74046182

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022533416A Active JP7704751B2 (ja) 2019-12-06 2020-12-04 再発性および/または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用
JP2025106921A Pending JP2025138745A (ja) 2019-12-06 2025-06-25 再発性および/または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025106921A Pending JP2025138745A (ja) 2019-12-06 2025-06-25 再発性および/または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用

Country Status (13)

Country Link
US (1) US20210171653A1 (https=)
EP (1) EP4069740A1 (https=)
JP (2) JP7704751B2 (https=)
KR (1) KR20220159948A (https=)
CN (1) CN115698065A (https=)
AU (1) AU2020398655A1 (https=)
BR (1) BR112022010907A2 (https=)
CA (1) CA3164026A1 (https=)
CO (1) CO2022009433A2 (https=)
IL (1) IL293615A (https=)
MX (1) MX2022006883A (https=)
TW (1) TWI887310B (https=)
WO (1) WO2021113754A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4536278A2 (en) 2022-06-07 2025-04-16 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
JP6279065B2 (ja) * 2013-03-13 2018-02-14 サノフイ 抗cd38抗体およびカーフィルゾミブを含む組成物
SG10201803288RA (en) * 2013-10-31 2018-05-30 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers
JP2021502961A (ja) * 2017-10-31 2021-02-04 ヤンセン バイオテツク,インコーポレーテツド 高リスク多発性骨髄腫の治療方法

Similar Documents

Publication Publication Date Title
JP2023123627A5 (https=)
IL277215B2 (en) Use of anti-IL-36R antibodies for the treatment of generalized pustular psoriasis
EP4245367A3 (en) Methods for treating cholestasis
JP2018507220A5 (https=)
JP2023055904A5 (https=)
JP2021523122A5 (https=)
JP2017534577A5 (https=)
CA2707400A1 (en) Method for treating bone fracture with anti-sclerostin antibodies
JP2018108086A5 (https=)
IL263272B2 (en) Antibodies to coagulation factor xi
JP2019524820A5 (https=)
IL314896A (en) Methods of use of anti-trem2 antibodies
JP2015515490A5 (https=)
JP2019534251A5 (https=)
JPWO2020250915A5 (https=)
JP2021523138A5 (https=)
JPWO2020160020A5 (https=)
JPWO2021113754A5 (https=)
JP2021521170A5 (https=)
JPWO2023081705A5 (https=)
RU2022118184A (ru) Применение изатуксимаба для лечения рецидивирующей и/или рефрактерной множественной миеломы
JP2021529766A5 (https=)
JPWO2021092134A5 (https=)
JPWO2019246557A5 (https=)
JPWO2022053990A5 (https=)